FDA 483 - Boehringer Ingelheim Animal Health do Brasil Ltda. - December 13, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
**FDA 483 Summary: Boehringer Ingelheim Animal Health do Brasil Ltda.**
**Inspection Details:** - **Company:** Boehringer Ingelheim Animal Health do Brasil Ltda. - **Location:** Avenida Doutor Roberto Moreira, 5005, Recanto dos Passaros, Paulinia, CEP 13140-970, Brazil - **Inspection Dates:** December 5-13, 2022 - **Type of Establishment:** Animal Drug Manufacturer
**Key Violations/Issues:** 1. **Quality Control Deficiencies:** - The Quality Unit lacked written procedures and failed to address laboratory errors and equipment malfunctions, leading to a 71% invalidation rate of out-of-specification (OOS) test results from January 2020 to November 2022. Personnel issues contributed to 47% of these errors. - Failure to submit a Field Alert to the FDA for OOS assay results during stability testing of Eqvalan (Ivermectin Paste 3%).
2. **Inadequate Investigation and Documentation:** - Failure to thoroughly investigate and document discrepancies and batch failures. Notably, sterility failures in Ivomec Gold Injectable were invalidated without sufficient evidence or comprehensive root cause analysis. - Assay failures for EQVALAN Oral Paste Syringe were invalidated without adequate investigation, attributing errors to sample preparation by inexperienced analysts without clear evidence.
**Regulatory Framework:** The observations highlight non-compliance with FDA regulations regarding quality control and reporting, specifically under the guidance for reporting OOS results and conducting thorough investigations.
**Required Actions:** - Implement comprehensive written procedures for the Quality Unit. - Conduct thorough investigations into OOS results and sterility failures, ensuring all evidence supports the root cause analysis. - Submit required Field Alerts for OOS results as per FDA guidelines. - Enhance training and oversight of personnel to prevent laboratory errors and ensure adherence to procedures.
These actions are crucial to address
- Inspection Date
- December 13, 2022
- Product Type
- Veterinary
ID · a3e09544-c39f-4fc0-90da-10151fe21655